Patents by Inventor Anjali Pandey

Anjali Pandey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE KINASE INHIBITORS
    Publication number: 20140323418
    Abstract: Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 30, 2014
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Brian Kane, Qing Xu, Shawn M. Bauer, Yonghong Song, Anjali Pandey, Ryan Dick
  • Pyrazine Kinase Inhibitors
    Publication number: 20140309209
    Abstract: Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 16, 2014
    Inventors: Yonghong Song, Qing Xu, Zhaozhong J. Jia, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • Inhibitors of JAK
    Patent number: 8853230
    Abstract: The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 7, 2014
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Jack W. Rose, Yonghong Song, Qing Xu, Mukund Mehrotra, Wolin Huang, Anjali Pandey
  • Benzamides and nicotinamides as Syk modulators
    Patent number: 8846928
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: September 30, 2014
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Yonghong Song, Qing Xu, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • Anti-obesity potential of Calebin A
    Publication number: 20140249219
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Anju Majeed, Bani Sarang, Anjali Pandey
  • Methods of preparing factor xa inhibitors and salts thereof
    Patent number: 8742120
    Abstract: The present invention provides for methods of preparing compounds of Formula I or a salt of the compound or a hydrate of the compound or salt thereof that are factor Xa inhibitors. Specifically the present invention provides a method of preparing the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, or a salt of the compound or a hydrate of the compound or salt thereof.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: June 3, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Urvish Pandya
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20140031361
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: June 13, 2013
    Publication date: January 30, 2014
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Qing Xu, Mukund Mehrotra, Jack W. Rose, Wolin Huang, Chandrasekar Venkataramani, Anjali Pandey
  • 1,2,4-TRIAZINE-6-CARBOXAMIDE KINASE INHIBITORS
    Publication number: 20130345191
    Abstract: Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 26, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Brian Kane, Jack Rose, Shawn M. Bauer, Yonghong Song, Qing Xu, Anjali Pandey
  • OXYPYRIMIDINES AS SYK MODULATORS
    Publication number: 20130317029
    Abstract: The present invention is directed to compounds of formula (I) and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which arc inhibitor of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: November 1, 2011
    Publication date: November 28, 2013
    Applicant: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Anjali Pandey, Qing Xu, Wolin Huang, Zhaozhong J. Jia, Yonghong Song
  • QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20130274252
    Abstract: The Present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 17, 2013
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE
    Publication number: 20130252917
    Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.
    Type: Application
    Filed: September 30, 2011
    Publication date: September 26, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Anjali Pandey
  • COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE
    Publication number: 20130244963
    Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia.
    Type: Application
    Filed: September 30, 2011
    Publication date: September 19, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Anjali Pandey
  • Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
    Patent number: 8536184
    Abstract: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: September 17, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: James Kanter, James Robinson, Anjali Pandey, Robert M. Scarborough
  • COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE
    Publication number: 20130237493
    Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.
    Type: Application
    Filed: September 30, 2011
    Publication date: September 12, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Anjali Pandey
  • Salts and crystalline forms of a factor Xa inhibitor
    Patent number: 8530501
    Abstract: The present invention provides salts and crystalline forms of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, and pharmaceutical compositions and method of use thereof.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: September 10, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Louisa Jane Quegan
  • Inhibitors of protein kinases
    Patent number: 8501944
    Abstract: The present invention is directed to a compound of the formula: and pharmaceutically acceptable tautomers, or salts thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to pharmaceutical compositions containing such a compound.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: August 6, 2013
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
  • ADAPTOGENIC ACTIVITY OF LABISIA PUMILA EXTRACT
    Publication number: 20130078323
    Abstract: The present invention provides a process of extracting the leaves of Labisia pumila with water into a free flowing powder using accelerated solvent system and drying. The invention also relates to the immunopotentiating effects of the extract against stress. The extract has effects on fatigue, hypoxia time, potentiation of swimming endurance, bod weight, weight of the thymus and spleen and levels of CD244+ NK cells, CD4+ and CD8+ T cells, expression of ThI cytokines IL-2 and IFN-gamma, corticosterone, glutathione, alanine aminotransferase and lipid peroxidation levels.
    Type: Application
    Filed: June 16, 2009
    Publication date: March 28, 2013
    Applicant: HOLISTA BIOTECH SDN. BHD.
    Inventors: Sarang Bani, Anjali Pandey, Kiranjeet Kour, Prashant Singh Chauhan, Balkrishan Chandan, Neelam Sharma, Kuldeep Singh, Surrinder Koul, Bishan Dutt Gupta, Payarelal Sangwan, Devinder Kumar Gupta, Shankar Lal, Rajendran Marnickavasagar
  • Methods of synthesizing factor Xa inhibitors
    Patent number: 8394964
    Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: March 12, 2013
    Assignees: Millennium Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song
  • Inhibitors of JAK
    Patent number: 8367689
    Abstract: The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: February 5, 2013
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Jack W. Rose, Yonghong Song, Qing Xu, Mukund Mehrotra, Wolin Huang, Anjali Pandey
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20130029944
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: June 20, 2012
    Publication date: January 31, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Yonghong Song, Qing Xu, Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Anjali Pandey